Center for Clinical Labrotary, the First Affiliated Hospital of Soochow University, 188# Shizi Road, Suzhou, 215006, Jiangsu, China.
Sci Rep. 2017 Dec 4;7(1):16877. doi: 10.1038/s41598-017-17001-0.
Corynebacterium pyruviciproducens (C. pyruviciproducens, CP), as a newly discovered immunomodulator, has been confirmed to have a stronger immunoregulation than Propionibacterium acnes (P. acnes) of the traditional immune adjuvant, by previous experiments with model antigen ovalbumin and sheep red blood cells. Here, it was designed to assess its ability to resist methicillin-resistant Staphylococcus aureus (MRSA), since MRSA as a vital gram positive pathogen is characterized by high morbidity and mortality. In this report, it was indicated that C. pyruviciproducens and its peptidoglycan (CP-PGN) could help to be against bloodstream infection of MRSA with raised survival rate, decreased bacteria load and alleviated systemic inflammation, and these effects of CP-PGN were more pronounced. However, the whole CP was inclined to prevent localized abdominal infection of MRSA from progressing to a systemic infection. And they showed the potential as a therapeutic drug alone or combined with vancomycin. The diversity of capacity of activating macrophages induced by CP and CP-PGN may result in distinct resistance to MRSA in different infection models. Furthermore, both CP and CP-PGN induced M1 macrophages. In conclusion, CP and its PGN could act as promising immune agents to treat and prevent MRSA infection.
解偶联蛋白（C. pyruviciproducens，CP）作为一种新发现的免疫调节剂，通过对模型抗原卵清蛋白和绵羊红细胞的实验，已被证实比传统免疫佐剂痤疮丙酸杆菌（P. acnes）具有更强的免疫调节作用。在这里，我们设计了评估其抵抗耐甲氧西林金黄色葡萄球菌（MRSA）的能力，因为 MRSA 作为一种重要的革兰氏阳性病原体，其发病率和死亡率都很高。在本报告中，表明 CP 和其肽聚糖（CP-PGN）可以帮助对抗耐甲氧西林金黄色葡萄球菌的血流感染，提高生存率，降低细菌负荷，减轻全身炎症，且 CP-PGN 的作用更为明显。然而，整个 CP 倾向于防止耐甲氧西林金黄色葡萄球菌的局部腹部感染进展为全身感染。它们具有作为单一药物或与万古霉素联合治疗的潜力。CP 和 CP-PGN 激活巨噬细胞的能力的多样性可能导致在不同感染模型中对 MRSA 具有不同的抵抗力。此外，CP 和 CP-PGN 均可诱导 M1 巨噬细胞。总之，CP 和其 PGN 可以作为有前途的免疫制剂，用于治疗和预防耐甲氧西林金黄色葡萄球菌感染。
